Multicenter, Randomized, Double-Blind, Parallel-Group Extension To Study Ac-058B201 To Investigate The Long-Term Safety, Tolerability, And Efficacy Of 10, 20, And 40 Mg/Day Ponesimod, An Oral S1p1 Receptor Agonist, In Patients With Relapsing-Remitting Multiple Sclerosis.
Posted Date: Mar 26, 2014
- Investigator: Joseph Nicolas
- Specialties: Multiple Sclerosis, Neurology
- Type of Study: Drug
PURPOSE OF THE STUDY The aims of this study are: • To offer subjects an option to continue treatment with ponesimod, or to initiate treatment with ponesimod if they did not receive active treatment during the core study. • To find out more about the long-term safety and tolerability of ponesimod. • To investigate the long-term effectiveness of ponesimod.
Criteria:
The Subjects All Subjects Who Participated In The Core Study And Completed Their Study Treatment In The Core Study Are Eligible To Enter This Extension Study
Keywords:
Relapsing-Remitting, Neurology, Multiple Sclerosis, Actelion
For More Information:
Alecia Boehl
513-558-0039
alecia.boehl@yahoo.com